文献速递肿瘤 PET/CT核素与放射性配体治疗

新型放射性杂合PSMA探针18F-rhPSMA-7在前列腺癌患者中的生物分布与PET图像质量定量及定性分析

Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer.
PubMed 文献 · J Nucl Med · 2019-12-13

该研究回顾性分析202例前列腺癌患者的18F-rhPSMA-7 PET/CT,按给药活度和摄取时间分组,定量分析背景、健康器官及肿瘤的SUVmean和靶本比,定性评估图像质量。结果显示肿瘤摄取在不同给药活度和摄取时间下保持稳定,生物分布与现有PSMA配体相似,推荐50-70分钟早期显像以获得最佳整体图像质量。

要点

  • 18F-rhPSMA-7肿瘤摄取在不同给药活度和摄取时间下保持稳定。
  • 随摄取时间延长,血池和肺SUVmean显著下降,肾、膀胱和骨SUVmean上升。
  • 推荐50-70分钟早期显像点以获得最佳整体图像质量。

核心结论

  • 18F-rhPSMA-7的生物分布与现有PSMA配体相似,肿瘤摄取在不同给药活度和摄取时间下保持稳定。
  • 推荐50-70分钟早期显像时间点用于18F-rhPSMA-7 PET/CT以获得最高整体图像质量。

研究设计与样本

  • 回顾性分析202例临床指征行18F-rhPSMA-7 PET/CT的前列腺癌患者。
  • 按给药活度分3组(低222-296 MBq、中297-370 MBq、高371-444 MBq),按摄取时间分4组(短50-70 min、中71-90 min、长91-110 min、超长≥111 min),共12组。
  • 定量分析测定背景、健康器官和3个代表性肿瘤病灶的SUVmean及器官或肿瘤与背景比值;定性分析用3或4分制评估整体图像质量、非特异性血池活度和骨或骨髓背景摄取。

主要发现

  • 随摄取时间延长,血池和肺SUVmean显著下降,肾、膀胱和骨SUVmean上升。
  • 随给药活度增加,血池和骨SUVmean呈上升趋势。
  • 377个肿瘤病灶的摄取在给药活度和摄取时间方面均无显著差异。
  • 定性分析中整体图像质量随摄取时间保持稳定,但评为良好图像质量的比例随给药活度增加而下降。
  • 随摄取时间延长,非特异性血池活度减少、骨髓背景摄取更频繁、对临床决策的负面影响增加。

关键数值与推荐

  • 给药活度分组:低222-296 MBq、中297-370 MBq、高371-444 MBq。
  • 摄取时间分组:短50-70 min、中71-90 min、长91-110 min、超长≥111 min。
  • 推荐早期显像时间点50-70 min以获得最高整体图像质量。

临床怎么用

  • 临床行18F-rhPSMA-7 PET/CT时可选择50-70分钟早期显像以获取最佳整体图像质量。
  • 肿瘤摄取在不同给药活度和摄取时间下稳定,支持在推荐时间窗内灵活安排显像。
  • 随摄取时间延长骨髓背景摄取更频繁且对临床决策负面影响增加,解读时需注意。

局限性

  • 本研究为回顾性分析。
  • 原文摘要未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiohybrid PSMA (rhPSMA) ligands, a new class of theranostic prostate-specific membrane antigen (PSMA)-targeting agents, feature fast 18F synthesis and utility for labeling with radiometals. Here, we assessed the biodistribution and image quality of 18F-rhPSMA-7 to determine the best imaging time point for patients with prostate cancer. Methods: In total, 202 prostate cancer patients who underwent a clinically indicated 18F-rhPSMA-7 PET/CT were retrospectively analyzed, and 12 groups based on the administered activity and uptake time of PET scanning were created: 3 administered activities (low, 222-296 MBq; moderate, 297-370 MBq; and high, 371-444 MBq) and 4 uptake time points (short, 50-70 min; intermediate, 71-90 min; long, 91-110 min; and extra long, ≥111 min). For quantitative analyses, SUVmean and organ- or tumor-to-background ratio were determined for background, healthy organs, and 3 representative tumor lesions. Qualitative analyses assessed overall image quality, nonspecific blood-pool activity, and background uptake in bone or marrow using 3- or 4-point scales. Results: In quantitative analyses, SUVmean showed a significant decrease in the blood pool and lungs and an increase in the kidneys, bladder, and bones as the uptake time increased. SUVmean showed a trend to increase in the blood pool and bones as the administered activity increased. However, no significant differences were found in 377 tumor lesions with respect to the administered activity or uptake time. In qualitative analyses, the overall image quality was stable along with the uptake time, but the proportion rated to have good image quality decreased as the administered activity increased. All other qualitative image parameters showed no significant differences for the administered activities, but they showed significant trends with increasing uptake time: less nonspecific blood activity, more frequent background uptake in the bone marrow, and increased negative impact on clinical decision making. Conclusion: The biodistribution of 18F-rhPSMA-7 was similar to that of established PSMA ligands, and tumor uptake of 18F-rhPSMA-7 was stable across the administered activities and uptake times. An early imaging time point (50-70 min) is recommended for 18F-rhPSMA-7 PET/CT to achieve the highest overall image quality.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Oh SW, Wurzer A, Teoh EJ, et al. Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer. J Nucl Med. 2019. PMID: 31836686. doi:10.2967/jnumed.119.234609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。